FDA The FDA has approved atezolizumab (Tecentriq) for adult and pediatric patients aged 2 years and older with unresectable or metastatic alveolar soft part sarcoma (ASPS). The safety and efficacy of the agent was examined in the open-label, single-arm study, referred to as Study ML39345 ...
FDA label Download (245 KB) Clinical Trials Clinical Trials Clinical Trial & Rare Diseases Add-on Data Package Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package PhaseStatusPurposeConditionsCountStart DateWhy Stopped100+ additio...
Atezolizumab is an FDA-approved anti-PD-L1 monoclonal antibody (mAb) used to treat PD-L1 positive metastatic TNBC in combination with chemotherapy. From:Trends in Cancer,2021 Also in subject areas: Medicine and Dentistry Neuroscience Nursing and Health Professions ...
The multicenter, open-label COSMIC-021 trial is evaluating the combination of atezolizumab and cabozantinib in patients with locally advanced or metastatic solid tumors. Currently, cabozantinib is FDA approved in combination with nivolumab (Opdivo) as a first-line treatment for patients with advanced ...
Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study Lancet, 398 (10306) (2021), pp. 1157-1169 View in ScopusGoogle Scholar 39. MJ Dickinson, C Carlo-Stella, F Morschhauser Glofitamab for relapsed...
ABCSG-52/ATHENE is a multicenter open-label, two-arm, randomized, single-stage phase 2 study (Fig. 1). Registration of the study in the European Union Clinical Trials Register was performed before the inclusion of the first patient (EudraCT no. 2019-002364-27). The study protocol was revie...
Cabozantinib plus atezolizumab demonstrated promising clinical activity and a suitable safety profile as first-line therapy in patients with cisplatin- eligible and -ineligible, inoperable locally advanced or metastatic urothelial cancer and as second- o
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 20, 924–937 (2019). ...
ATEZO + BEV is FDA approved for first-line treatment of advanced HCC based on the IMbrave 150 study. Locoregional radiotherapy (e.g., Y90 TARE) enhances the diversity of the intratumoral T cell receptor repertoire and increases tumor antigen release. We hypothesize that the Y90 TARE + BEV ...
Among the 38 adults in their single-arm, open-labelTEMLA trial, median progression-free survival (PFS) with the combination was 13 months, and overall survival at 12 months was 72%. The combination was "associated with encouraging survival rates and durable responses, with a favorable safety ...